Oruka Therapeutics, Inc. ORKA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s cash & equivalents?
- Oruka Therapeutics, Inc. (ORKA) reported cash & equivalents of $49.52M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Oruka Therapeutics, Inc.'s cash & equivalents decreased by 40.7% year-over-year, from $83.57M to $49.52M.
- What is the long-term trend for Oruka Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Oruka Therapeutics, Inc.'s cash & equivalents has grown at a -0.9% compound annual growth rate (CAGR), from $49.07M to $46.94M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.